A growing number of Chinese biotech companies are trying to bridge the drug innovation gap between the East and the West. Now, Overland Pharmaceuticals is joining the fray.
The company, which launched earlier this month, is backed by Hillhouse Capital and will be led by co-founders Hua Mu and Ed Zhang, two venture partners who joined the Asia-focused private equity group earlier this year.
“Our idea with Overland was to build a leading, fully integrated biopharma company to tap into promising biomedical innovations and to leverage the tremendous business opportunity [that China’s] booming biotech sector presents,” Zhang, chief operating officer and chief business officer, told STAT.
